Departments of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan Province, People's Republic of China.
Department of Gastrointestinal Oncology, Nanyang Second General Hospital, Nanyang, 473009, Henan Province, People's Republic of China.
Sci Rep. 2023 Nov 28;13(1):20969. doi: 10.1038/s41598-023-48366-0.
Hepatocellular carcinoma (HCC) is a lethal malignancy worldwide with an increasing number of new cases each year. Apolipoprotein (APOL) isoforms have been explored for their associations with HCC.The GSE14520 cohort was used for training data; The Cancer Genome Atlas (TCGA) database was used for validated data. Diagnostic, prognostic significance and mechanisms were explored using these cohorts. Risk score models and nomograms were constructed using prognosis-related isoforms and clinical factors for survival prediction. Oncomine and HCCDB databases were further used for validation of diagnostic, prognostic significance. APOL1, 3, and 6 were differentially expressed in two cohorts (all P ≤ 0.05). APOL1 and APOL6 had diagnostic capacity whereas APOL3 and APOL6 had prognostic capacity in two cohorts (areas under curves [AUCs] > 0.7, P ≤ 0.05). Mechanism studies demonstrated that APOL3 and APOL6 might be involved in humoral chemokine signaling pathways (all P ≤ 0.05). Risk score models and nomograms were constructed and validated for survival prediction of HCC. Moreover, diagnostic values of APOL1 and weak APOL6 were validated in Oncomine database (AUC > 0.700, 0.694); prognostic values of APOL3 and APOL6 were validated in HCCDB database (all P < 0.05). Differentially expressed APOL1 and APOL6 might be diagnostic biomarkers; APOL3 and APOL6 might be prognostic biomarkers of RFS and OS for HCC via chemokine signaling pathways.
肝细胞癌（HCC）是一种全球范围内具有致命性的恶性肿瘤，每年新增病例数量不断增加。载脂蛋白（APOL）同工型已被探索与其相关性HCC。GSE14520 队列用于训练数据；癌症基因组图谱（TCGA）数据库用于验证数据。使用这些队列探索了诊断、预后意义和机制。使用与预后相关的同工型和临床因素构建了风险评分模型和列线图，用于预测生存。Oncomine 和 HCCDB 数据库进一步用于验证诊断和预后意义。两个队列中差异表达的 APOL1、3 和 6（均 P≤0.05）。APOL1 和 APOL6 具有诊断能力，而 APOL3 和 APOL6 在两个队列中具有预后能力（曲线下面积[AUC] > 0.7，P≤0.05）。机制研究表明，APOL3 和 APOL6 可能参与体液趋化因子信号通路（均 P≤0.05）。构建并验证了风险评分模型和列线图，用于预测 HCC 的生存。此外，在 Oncomine 数据库中验证了 APOL1 和弱 APOL6 的诊断价值（AUC>0.700，0.694）；在 HCCDB 数据库中验证了 APOL3 和 APOL6 的预后价值（均 P<0.05）。差异表达的 APOL1 和 APOL6 可能是诊断生物标志物；APOL3 和 APOL6 可能通过趋化因子信号通路成为 HCC 的 RFS 和 OS 的预后生物标志物。
